Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 2/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CMA1 | P23946 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2717301 | 0.84 | KMT2A (0.57) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL2377998 | 0.83 | APLNR (0.58) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL3237393 | 0.83 | KMT2A (0.55) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL30496480 | 0.83 | PKM (0.56) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL3237396 | 0.83 | PKM (0.56) | APLNRIDO1PLCG1PKMCA1 | |
| Hydrochloric Acid SCHEMBL27633192 | 0.83 | KMT2A (0.55) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL294920 | 0.81 | APLNR (0.52) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL2339126 | 0.81 | CA1 (0.56) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL3298473 | 0.81 | APLNR (0.52) | APLNRIDO1PLCG1PKMCA1 | |
| SCHEMBL13611748 | 0.81 | KMT2A (0.54) | APLNRIDO1PLCG1PKMCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619095-B2 | Process for the preparation of indolone derivative | ALEMBIC LIMITED (IN) | 2009-11-17 | — | — | US | claimed |
| EP-1848691-B1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LTD (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | ALEMBIC LIMITED (IN) | 2008-10-23 | — | — | US | claimed |
| EP-1848691-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | Alembic Limited (IN) | 2007-10-31 | — | — | EP | claimed |
| WO-2006123356-A1 | PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE | ALEMBIC LIMITED (IN) | 2006-11-23 | — | — | WO | claimed |
| EP-0255134-B1 | CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-03 | — | — | EP | claimed |
| EP-4400492-A1 | ACRIDINE COMPOUND | OSAKA UNIVERSITY (JP) | 2024-07-17 | — | — | EP | disclosed |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-06-27 | — | — | US | disclosed |
| EP-4370507-A1 | HYDROGENATED QUINOXALINES | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-05-22 | — | — | EP | disclosed |
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| CN-117940408-A | Acridine compounds | 国立大学法人大阪大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-04 | — | — | US | disclosed |
| US-4487772-A | CARDIOTONIC AGENTS | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| US-4468402-A | Carbostyril derivatives, process for producing the same and cardiotonic compositions containing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-28 | — | — | US | disclosed |
| EP-0115334-A1 | Benzo-heterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-08-08 | — | — | EP | disclosed |
| US-4454130-A | CARDIOTONIC, HYPOTENSIVE AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-06-12 | — | — | US | disclosed |
| EP-0109653-A2 | Process for preparing urokinase complex | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4435404-A | ANTICOAGULANTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-03-06 | — | — | US | disclosed |
| US-4415572-A | CARDIOTONIC AND INOTROPIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148699-A1 | OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION | PDE3B, PDE4A, PDE3A | APLNR 4608/4885IDO1 84/4885PLCG1 781/4885 |
| US-20080262244-A1 | Process for the Preparation of Indolone Derivative | HTR3C, HTR3B, HTR1B | APLNR 4844/4885IDO1 6/4885PLCG1 2369/4885 |
| US-20240109842-A1 | ACRYLAMIDE COMPOUNDS | HPGDS, MYADM, ACR | APLNR 3522/4885IDO1 4711/4885PLCG1 1663/4885 |
| US-20240208999-A1 | HETEROCYCLIC COMPOUND | AHR, PDGFRA, PDGFRB | APLNR 186/4885IDO1 1608/4885PLCG1 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.